Clinical trial
Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS
NCT00210301 · Institute for Clinical Research, Other · Unknown status
Key facts
| NCT number | NCT00210301 |
|---|---|
| Title | Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS |
| Official title | Combination Therapy (Provigil + Avonex) in the Treatment of Attention Problems in Patients With Relapsing-Remitting MS |
| Lead sponsor | Institute for Clinical Research, Other |
| Status | Unknown status |
| Study type | Interventional |
| Conditions | Relapsing-Remitting Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Provigil (modafinil) |
| Enrollment | 60 |
| Start date | Jan 1, 2003 |
| First posted | Sep 21, 2005 |
| Last update posted | Sep 7, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: